Analyst Ratings for BioAtla
Within the last quarter, BioAtla (NASDAQ:BCAB) has observed the following analyst ratings: Bullish Somewhat Bullish Indifferent Somewhat Bearish…
Stocks That Hit 52-Week Lows On Friday
Friday's session saw 169 companies set new 52-week lows.
The Latest Analyst Ratings for BioAtla
Within the last quarter, BioAtla (NASDAQ:BCAB) has observed the following analyst ratings: Bullish Somewhat Bullish Indifferent Somewhat Bearish…
Earnings Scheduled For August 1, 2023
Companies Reporting Before The Bell
• Toyota Motor (NYSE:TM) is estimated to report earnings for its first quarter.
• BP (NYSE:BP) is projected to report quarterly earnings at $1.21 per share on revenue of $54.48 billion.
BioAtla Added To Membership Of U.S. Small-Cap Russell 2000 Index
BioAtla, Inc. (NASDAQ:BCAB), a global clinical-stage biotechnology company focused on the development of Conditionally Active Biologic (CAB) antibody therapeutics for the treatment of solid tumors, today announced that
Where BioAtla Stands With Analysts
Analysts have provided the following ratings for BioAtla (NASDAQ:BCAB) within the last quarter: Bullish Somewhat Bullish Indifferent Somewhat…
Earnings Scheduled For May 11, 2023
Companies Reporting Before The Bell
• Takeda Pharmaceutical (NYSE:TAK) is likely to report earnings for its fourth quarter.
• Exela Technologies (NASDAQ:XELA) is expected to report earnings for its first quarter.
Around $1.5M Bet On This Healthcare Stock? Check Out These 4 Penny Stocks Insiders Are Aggressively Buying
The Dow Jones closed higher by more than 100 points on Thursday. When insiders purchase or sell shares, it indicates their confidence or concern around the company's prospects. Investors and traders interested in penny stocks can consider this a factor in their overall investment or trading decision.
Expert Ratings for BioAtla
Within the last quarter, BioAtla (NASDAQ:BCAB) has observed the following analyst ratings: Bullish Somewhat Bullish Indifferent Somewhat Bearish…
Earnings Scheduled For March 23, 2023
Companies Reporting Before The Bell
• Cognition Therapeutics (NASDAQ:CGTX) is likely to report earnings for its fourth quarter.